

Listing and evaluation of the results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.

Survey of 22 September 2023

Adviser: Prof. Dr. med. Kai Gutensohn
Werlhof-Institut
Schillerstr. 23
30159 Hannover

Tel.: +49 511 330599 10
Mail: k.gutensohn@werlhof-institut.de

217

Haematology 11 - Stem/Progenitor Cells (CD 34)

| Analyte | Sample | Unit | Your value | Target value | TV-Type | Lower limit | Upper limit | Deviation | Z-Score | Meets criteria | |
|---|--------|------|------------|--------------|---------|-------------|-------------|-----------|---------|----------------|--|
| CD34+ Events | 51 | /µl | 45.0 | 60.9 | SV | 48.7 | 73.1 | -26.1% | -2 | - | |
| | 52 | | 28.0 | 44.8 | SV | 35.8 | 53.8 | -37.5% | -3,02 | - | |
| Leucocytes | (1) 51 | /µl | 10717 | | | | | | | | |
| | (1) 52 | | 7972 | | | | | | | | |
| CD45+ events (single platform) | (1) 51 | /µl | 10158 | | | | | | | | |
| | (1) 52 | | 7623 | | | | | | | | |
| Viable CD45+ Events | (1) 51 | /µl | 10025 | | | | | | | | |
| | (1) 52 | | 7543 | | | | | | | | |
| Viable CD34+ Events | 51 | /µl | 44.0 | 57.9 | SV | 46.3 | 69.5 | -24.0% | -2,01 | - | |
| | 52 | | 27.0 | 41.2 | SV | 33.0 | 49.4 | -34.5% | -3,12 | - | |
| Viable CD34+ Events per viable CD45+ Events | (1) 51 | % | 0.380 | | | | | | | | |
| | (1) 52 | | 0.356 | | | | | | | | |
| Percentage (%) of CD34+ stem cells of total WBC's | (1) 51 | % | 0.430 | | | | | | | | |
| | (1) 52 | | 0.366 | | | | | | | | |

| Analyte | Sample | Your unit | Stated value | Conversion factor | Method | Manufacturer | Device | Sample reception date | Sample processing date |
|---|--------|-----------|--------------|-------------------|--------|--------------|--------|-----------------------|------------------------|
| CD34+ Events | 51 | | 45.0 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 28.0 | 1.00 | | | | | |
| Leucocytes | 51 | | 10717 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 7972 | 1.00 | | | | | |
| CD45+ events (single platform) | 51 | | 10158 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 7623 | 1.00 | | | | | |
| Viable CD45+ Events | 51 | | 10025 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 7543 | 1.00 | | | | | |
| Viable CD34+ Events | 51 | | 44.0 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 27.0 | 1.00 | | | | | |
| Viable CD34+ Events per viable CD45+ Events | 51 | | 0.380 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 0.356 | 1.00 | | | | | |
| Percentage (%) of CD34+ stem cells of total WBC's | 51 | | 0.430 | 1.00 | 222 | BN | BN04 | 09/13/23 | 09/13/23 |
| | 52 | | 0.366 | 1.00 | | | | | |

(1) In general, no certificate is issued for this parameter in this EQA scheme.

Additional information on the evaluation is available for download in the RV-Online system in the column "Report".

Individual summary of results

51396: Dr. Endre Mikus
LabMagister Training and Science Ltd.



Survey of 22 September 2023

217

Haematology 11 - Stem/Progenitor Cells (CD 34)


| CD34+ Events (/μl, N = 116) | | | | | | | | | | |
|-----------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| all methods | 51 | 60.9 | 48.7 - 73.1 | 60.9 | 13.1 | 116 | 85.3 | 79.3 | | |
| | 52 | 44.8 | 35.8 - 53.8 | 44.8 | 12.4 | 116 | 83.6 | | | |

Rate of success: 79,3%




| Leucocytes (/μl, N = 48) | | | | | | | | | | |
|--------------------------|--------|--------------|--------------|-------------------------|----|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| all methods | 51 | | | 10247 | | 48 | | | | |
| | 52 | | | 7601 | | 48 | | | | |

Rate of success: 93,8%




| CD45+ events (single platform) (/μl, N = 108) | | | | | | | | | | |
|---|--------|--------------|--------------|-------------------------|----|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| all methods | 51 | | | 10186 | | 108 | | | | |
| | 52 | | | 7611 | | 108 | | | | |

Rate of success: 89,8%





| Viable CD45+ Events (/μl, N = 112) | | | | | | | | | |
|------------------------------------|--------|--------------|--------------|-------------------------|----|------|----------|-------|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | |
| | | | | AVG | CV | Num. | Sam. | total | |
| all methods | 51 | | | 6766 | | 112 | | | |
| | 52 | | | 5829 | | 112 | | | |

Rate of success: 77,7%




| Viable CD34+ Events (/μl, N = 114) | | | | | | | | | | |
|------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| all methods | 51 | 57.9 | 46.3 - 69.5 | 57.9 | 12.0 | 114 | 89.5 | 84.2 | | |
| | 52 | 41.2 | 33.0 - 49.4 | 41.2 | 11.0 | 114 | 89.5 | | | |

Rate of success: 84,2%



| Viable CD34+ Events per viable CD45+ Events (% , N = 113) | | | | | | | | | |
|---|--------|--------------|--------------|-------------------------|----|------|----------|-------|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | |
| | | | | AVG | CV | Num. | Sam. | total | |
| all methods | 51 | | | 0.858 | | 113 | | | |
| | 52 | | | 0.715 | | 113 | | | |

Rate of success: 75,2%





Percentage (%) of CD34+ stem cells of total WBC's (% , N = 76)

| Collective | Sam- ple | Target value | Target range | Participants collective | | | Rate (%) | |
|-------------|-------------|-----------------|--------------|-------------------------|----|------|----------|-------|
| | | | | AVG | CV | Num. | Sam. | total |
| all methods | 51 | | | 0.623 | | 76 | | |
| | 52 | | | 0.605 | | 76 | | |

Rate of success: 72,4%

